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MicroarrayAristolochic acids (AAs) are the active components of herbal drugs derived from Aristolochia species that have
been used for medicinal purposes since antiquity. However, AAs have recently been discovered to be highly
nephrotoxic and induced urothelial cancer in humans and malignant tumors in the kidney and urinary tract of
rodents. In this study, we exposed rat renal proximal tubule cells in vitro to a sub-cytotoxic level of AAs at
three different time points (6h, 24h and 72h).We then analyzed the gene expression proﬁle after the compound
exposure. Functional analysis with Ingenuity Pathways Analysis and DAVID tools revealed that at the late time
point (72 h) there are many signiﬁcantly altered genes involved in cancer-related pathways such as p53
signaling.
MIAMI-compliant microarray data are deposited in the NCBI GEO database under accession number GSE68687
and can be found at: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68687.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Speciﬁcationsrganism/cell line/tissue Rat/NRK-52E cells (ATCC, CRL-1571)
x Male
quencer or array type Affymetrix Rat Genome 230 2.0 Array
ata format Raw and analyzed
xperimental factors Normal rat renal proximal tubule cells exposed to
1.65 μM aristolochic acids for 6 h, 24 h and 72 h as well
as time-matched controls exposed to DMSO alonexperimental features NRK-52E cells were exposed to aristolochic acids
dissolved in DMSO (0.1%) at the IC10 concentration at
72 h (1.65 μM) or DMSO only as control. After 6 h, 24 h
and 72 h RNA was extracted from the cells. Three
studies were conducted at each time point.onsent NA
mple source location NRK-52E cells (ATCC, CRL-1571), Liverpool, UKSa1. Direct link to deposited data
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68687.
2. Introduction
Aristolochic acids (AAs) are a mixture of structurally related
nitrophenanthrene carboxylic acids, mainly 8-methoxy-6-. This is an open access article undernitrophenanthro [3,4-d] 1,3-dioxolo-5-carboxylic acid (aristolochic
acid I) and its 8-demethoxylated form (aristolochic acid II) (Fig. 1)
that are secondarymetabolites of Aristolochia and Asarum plant species.
Herbal drugs containing aristolochic acids have been used since an-
tiquity, however in 1982, AAswere reported to behighly carcinogenic in
rats causing renal and forestomach cancers [1,2]. Later similar ﬁndings
were reported in mice [3]. In 1991, a unique and rapidly progressive
renal ﬁbrosis referred as Aristolochic Acid Nephropathy (AAN), was ob-
served in around 5% of patients that tookweight-reducing pills contain-
ingAAs [4]. Over 100 cases of AANhave been identiﬁedwith around half
needing renal transplantation [4,5]. AA consumption (as harvest con-
tamination) is also hypothesized to be a causative agent in the develop-
ment of a similar type of kidney ﬁbrosis with malignant transformation
of the urothelium— Balkan Endemic Nephropathy [6]. To date AAs have
been shown to be among the 2% of the most potent known carcinogens
[7]. IARC has classiﬁed herbal remedies containing species of the genus
Aristolochia as carcinogenic to humans (Group 1) [8], whereas naturally
occurring mixtures of AAs are classiﬁed into Group 2A (probably carci-
nogenic to humans). AA is a direct-acting mutagen in TA100 and
TA1537 Salmonella typhimurium strains, but is not mutagenic in the
nitroreductase-deﬁcient strains (TA98NR and TA100NR) [9]. AAs were
found to be positive in the L5178Y mouse lymphoma assay and MN
assay [10]. Renal tubular epithelial cells are very sensitive to AAs and
undergo apoptosis or necrosis in response to this compound, with AAI
being the more cytotoxic congener [11]. The carcinogenic effect of AAs
is not fully elucidated but is associated with the formation of covalentthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Chemical structure of aristolochic acid I and II.
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and the presence of AA-DNA adducts in renal cortex and p53mutations
in tumor tissue were reported in patients with endemic nephropathy
[12].3. Materials and methods
3.1. Materials
A mixture of AAI and AAII was purchased from Sigma-Aldrich, UK.
TRIzol reagent and GlutaMAX were obtained from (Invitrogen, UK)
and RNeasy Total RNA Mini Kit and RNA later from (Qiagen, UK).3.2. Cell culture
NRK-52E cells (ATCC, CRL-1571) were cultured in Dulbecco's
Modiﬁed Eagle Medium (DMEM) with 10% fetal calf serum, penicillin
100 IU ml−1, and streptomycin solution 100 μg ml−1 in a humidiﬁed
5% CO2 incubator at 37 °C.3.3. Cytotoxicity-determination of IC10
A dose–response curve for AAs was determined using theMTT assay
[13]. Cells were exposed for 72 h in 96-well plates to a wide range of
concentrations of AAs dissolved in DMSO and diluted to give a ﬁnal con-
centration of 0.1% v/v DMSO. Control cells were exposed to DMSO alone
(0.1% v/v). At least three separate experiments were conducted. The
dose that caused approximately 10% cytotoxicity (IC10) at 72 h was se-
lected for the transcriptomics studies.Table 23.4. Cell treatment
NRK-52E cells were cultured to conﬂuence on 6-well plates. For
transcriptomics studies, cells were exposed to AAs dissolved in DMSO
(0.1% v/v) at the IC10 concentration at 72 h (1.65 μM) or DMSO
(0.1% v/v) alone. After 6 h, 24 h and 72 h the medium was removed
and RNA was extracted from cells. For replication, three studies were
conducted at each time point.Table 1
KEGG pathways enriched after 72 h exposure to AAs.
KEGG pathway No. of genes
involved in
pathway
Total no. of genes
involved in the
pathway (%)
P-value
(Benjamini)
p53 signaling pathway 16 1.9 8.5E−8 (1.3E−5)
Pathways in cancer 30 3.6 8.6E−5 (6.4E−3)3.5. RNA isolation and microarray
From in vitro studies total RNA was isolated from DMSO (control)
and AA-treated cells. TRIzol reagent was used for RNA isolation. Total
RNAwas puriﬁed using the RNeasy Total RNAMini Kit (Qiagen) accord-
ing to the manufacturer's instructions. RNA was checked for purity and
integrity using Agilent 2001 Bioanalyzer (Agilent Technologies GmbH,
Germany) before processing. Transcriptomics data was generated
using GeneChip Rat Genome 230 2.0 The rat array provides comprehen-
sive coverage of the transcribed rat genome and comprised of more
than 31,000 probe sets, analyzing over 30,000 transcripts and variants
from over 28,000 well-substantiated rat genes.
3.6. Microarray hybridization
3.6.1. Target preparation
cDNA was prepared using the Affymetrix IVT express kit (Affymetrix,
Santa Clara). cDNA synthesis and labeling were performed according to
themanufacturer's procedures. Subsequent labeling of the samples was
conducted by synthesis of Biotin-labeled complementary RNA (cRNA)
using the GeneChip IVT labeling kit (Affymetrix). Puriﬁed cRNA was
quantiﬁed using a spectrophotometer, and unfragmented samples
were checked on the Bioanalyzer. Subsequently, cRNA samples were
fragmented for target preparation according to the Affymetrix manual
and checked on the Bioanalyzer. Samples were stored at−20 °C until
ready to perform hybridization.
3.6.2. Hybridization
cRNA targets were hybridized on high-density oligonucleotide gene
chips (Affymetrix Human Genome U133 Plus 2.0 and GeneChip Rat
Genome 230 2.0 Arrays) according to the Affymetrix Eukaryotic Target
Hybridization manual. The gene chips were washed and stained using
the Affymetrix Fluidics Station 450 and Genechip Operating Software
and scanned by means of an Affymetrix GeneArray scanner.
3.6.3. Microarray analysis
The intensity values of different genes (probe sets) generated by
AffymetrixGeneChipOperating Softwarewere imported intoGeneSpringIngenuity pathways enriched after 72 h exposure to AAs.
Ingenuity canonical pathway No. of genes involved
in the pathway
P-value
p53 signaling 17/98 9.65E−08
Glutathione biosynthesis 3/3 4.96E−05
ATM signaling 10/59 5.20E−05
Cell cycle: G2/M DNA damage
checkpoint regulation
9/49 6.44E−05
Molecular mechanisms of cancer 8/99 6.74E−05
Table 3
GO enriched after 72 h exposure to AAs.
GO No. of genes involved
in pathway
Total no. of genes involved
in the pathway (%)
P-value (Benjamini)
Regulation of apoptosis 61 7.4 1.80E−08 (5.10E−05)
Release of cytochrome c from mitochondria 8 1 1.40E−05 (3.70E−03)
Regulation of cell proliferation 51 6.2 3.30E−05 (7.60E−03)
Apoptotic mitochondrial changes 8 1 1.50E−04 (2.40E−02)
Blood vessel morphogenesis 20 2.4 2.70E−04 (4.20E−02)
Tissue remodeling 11 1.3 2.80E−04 (4.10E−02)
Response to abiotic stimulus 33 4 2.90E−04 (4.00E−02)
Cellular response to stress 35 4.2 3.20E−04 (4.00E−02)
DNA damage response, signal transduction resulting in induction of apoptosis 7 0.8 3.60E−04 (4.30E−02)
Regulation of cell adhesion 15 1.8 4.50E−04 (4.60E−02)
Response to DNA damage stimulus 24 2.9 4.80E−04 (4.70E−02)
256 K.M. Bloch et al. / Genomics Data 5 (2015) 254–256version 11 software (Agilent) for data analysis. The raw data ﬁles (CEL
ﬁles) containing signal values for individual probes were pre-processed
to generate one value per probeset. Pre-processing of arrays was done
using GC-RMA (Robust Multiarray Analysis algorithm). To identify the
differentially expressed (DE) probe sets, two sampled t-test (unpaired
t-test) with a P-value b0.05 and Benjamini–Hochberg correction for
multiple testing correction and a fold cut off of 2was used. Comparisons
were made between control DMSO-exposed and AA-exposed cells.
Three studies were conducted at each time point.
3.6.4. Functional annotation
To understand the biological meaning behind the list of DE genes,
Kyoto Encyclopaedia of Genes andGenomes database (KEGG) pathways
analysis and Gene Ontology (GO) from DAVID website (The Database
for Annotation, Visualization and Integrated Discovery) v 6.7 (http://
david.abcc.ncifcrf.gov/) were used. Only GO and pathways with P-
value b0.05 (Benjamin–Hochberg corrected) and with 5 or more
genes were analyzed and discussed. In addition, Ingenuity Pathway
Analysis (IPA) was used. Only pathways and functions with P b 0.05
(Fisher's exact test right-tailed) were analyzed and discussed.
3.6.5. Data deposition
MIAMI-compliant microarray data were deposited in the NCBI GEO
database under accession number GSE68687; http://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc=GSE68687.
4. Results
4.1. Gene expression proﬁle induced after aristolochic acids exposure
No genes were differentially expressed after 6 h and 24 h exposure
to AAs, however at 72 h, 1204 genes were found to be differentially
expressed. Both IPA and KEGG pathways identify p53 signaling as a
top statistically signiﬁcantly enriched pathway (Tables 1 and 2). Addi-
tionally after 72 h exposure genes involved in apoptosis, stressresponse, DNA damage and glutathione biosynthesis were identify
(Tables 2 and 3).
5. Conclusion
Our results suggest that microarray analysis is a useful tool for de-
tecting AA exposure in vitro and the gene expression analysis can iden-
tify the responses to toxicity and carcinogenicity of AAs in rat renal
proximal tubule cells. In addition, the signiﬁcantly altered genes were
identify to be associated with cancer pathways and speciﬁcally p53 sig-
naling, DNA damage responses and apoptosis.
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